WO2015105772A1 - Selective nr2b antagonists - Google Patents

Selective nr2b antagonists

Info

Publication number
WO2015105772A1
WO2015105772A1 PCT/US2015/010262 US2015010262W WO2015105772A1 WO 2015105772 A1 WO2015105772 A1 WO 2015105772A1 US 2015010262 W US2015010262 W US 2015010262W WO 2015105772 A1 WO2015105772 A1 WO 2015105772A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
hz
min
rt
method
ml
Prior art date
Application number
PCT/US2015/010262
Other languages
English (en)
French (fr)
Inventor
Dalton King
Iii Lorin A. Thompson
Jianliang Shi
Srinivasan Thangathirupathy
Jayakumar Sankara WARRIER
Imadul Islam
John E. Macor
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
PCT/US2015/010262 2014-01-09 2015-01-06 Selective nr2b antagonists WO2015105772A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201461925363 true 2014-01-09 2014-01-09
US61/925,363 2014-01-09

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20150703328 EP3092224A1 (en) 2014-01-09 2015-01-06 Selective nr2b antagonists
CA 2936293 CA2936293A1 (en) 2014-01-09 2015-01-06 Selective nr2b antagonists
JP2016545819A JP2017502063A5 (und) 2015-01-06
KR20167021356A KR20160105885A (ko) 2014-01-09 2015-01-06 선택적 nr2b 길항제
CN 201580012735 CN106061961A (zh) 2014-01-09 2015-01-06 选择性nr2b拮抗剂

Publications (1)

Publication Number Publication Date
WO2015105772A1 true true WO2015105772A1 (en) 2015-07-16

Family

ID=52463126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/010262 WO2015105772A1 (en) 2014-01-09 2015-01-06 Selective nr2b antagonists

Country Status (6)

Country Link
US (5) US9221796B2 (und)
EP (1) EP3092224A1 (und)
KR (1) KR20160105885A (und)
CN (1) CN106061961A (und)
CA (1) CA2936293A1 (und)
WO (1) WO2015105772A1 (und)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066366A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists
WO2017066368A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028140A1 (fr) 1996-02-02 1997-08-07 Pierre Fabre Medicament Nouvelles piperidines derivees de la 1-/(piperazin-1-yl-)aryl(oxy/amino)carbonyl/-4-aryl-piperidine comme antagonistes selectifs des recepteurs 5-ht-1d.beta
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
WO2001081295A1 (en) * 2000-04-26 2001-11-01 Warner-Lambert Company Cyclohexylamine derivative as subtype selective nmda receptor antagonists
WO2004108705A1 (en) 2003-06-04 2004-12-16 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
WO2009006437A1 (en) 2007-06-29 2009-01-08 Emory University Nmda receptor antagonists for neuroprotection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
JP2007508288A (ja) 2003-10-08 2007-04-05 ファイザー株式会社 縮合ラクタム化合物
WO2007099828A1 (ja) 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028140A1 (fr) 1996-02-02 1997-08-07 Pierre Fabre Medicament Nouvelles piperidines derivees de la 1-/(piperazin-1-yl-)aryl(oxy/amino)carbonyl/-4-aryl-piperidine comme antagonistes selectifs des recepteurs 5-ht-1d.beta
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
WO2001081295A1 (en) * 2000-04-26 2001-11-01 Warner-Lambert Company Cyclohexylamine derivative as subtype selective nmda receptor antagonists
WO2004108705A1 (en) 2003-06-04 2004-12-16 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
WO2009006437A1 (en) 2007-06-29 2009-01-08 Emory University Nmda receptor antagonists for neuroprotection

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
A. KAMAL, TETRAHEDRON: ASYMMETRY, vol. 14, 2003, pages 2587,2594
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 August 2012 (2012-08-01), XP002736417, Database accession no. 1385072-30-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 September 2014 (2014-09-19), XP002736418, Database accession no. 1623322-96-2 *
F. S. MENNITI ET AL., CNS DRUG REVIEWS, vol. 4, no. 4, 1998, pages 307 - 322
G. SANACORA, NATURE REV. DRUG DISC, vol. 7, 2008, pages 426 - 437
GAG SULYOK ET AL., JMED CHEM, vol. 44, 2001, pages 1938 - 1950
HAYASHI E; SHIMAMURA M; KURATANI K; KINOSHITA M; HARA H: "Automated experimental system capturing three behavioral components during murine forced swim test", LIFE SCI., vol. 88, no. 9-10, 28 February 2011 (2011-02-28), pages 411 - 7
MUTEL V; BUCHY D; KLINGELSCHMIDT A; MESSER J; BLEUEL Z; KEMP JA; RICHARDS JG, JOURNAL OF NEUROCHEMISTRY, vol. 70, no. 5, 1998, pages 2147 - 2155
N RIOS-LOMBARDIA ET AL., J ORG CHEM, vol. 76, 2011, pages 5709 - 5718
PORSOLT RD; BERTIN A; JALFRE M: "Behavioral despair in mice: a primary screening test for antidepressants", ARCH INT PHARMACODYN THER, vol. 229, 1977, pages 327 - 36
PRESKOM ET AL., J. CLIN. PSYCHOPHARMACOL., vol. 28, 2008, pages 631 - 637
YUAN P; TRAGON T; XIA M; LECLAIR CA; SKOUMBOURDIS AP; ZHENG W; THOMAS CJ; HUANG R; AUSTIN CP; CHEN G: "Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents", PHARMACOL BIOCHEM BEHAV., vol. 98, no. 3, 2011, pages 349 - 55, XP028156097, DOI: doi:10.1016/j.pbb.2011.02.001
ZARATE ET AL., ARCH. GEN. PSYCHIATRY, vol. 63, 2006, pages 856 - 864

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066366A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists
WO2017066368A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists

Also Published As

Publication number Publication date Type
EP3092224A1 (en) 2016-11-16 application
JP2017502063A (ja) 2017-01-19 application
CN106061961A (zh) 2016-10-26 application
CA2936293A1 (en) 2015-07-16 application
US20150191452A1 (en) 2015-07-09 application
US20180000807A1 (en) 2018-01-04 application
US20180110766A1 (en) 2018-04-26 application
KR20160105885A (ko) 2016-09-07 application
US9221796B2 (en) 2015-12-29 grant
US20170258777A1 (en) 2017-09-14 application
US20160081995A1 (en) 2016-03-24 application

Similar Documents

Publication Publication Date Title
US20060199818A1 (en) N-substituted piperidine derivatives as serotonin receptor agents
US20040106600A1 (en) N-substituted piperidine derivatives as serotonin receptor agents
Chapman et al. Highly diastereoselective additions to polyhydroxylated pyrrolidine cyclic imines: ready elaboration of aza‐sugar scaffolds to create diverse carbohydrate‐processing enzyme probes
US20090312310A1 (en) Imidazothiazole derivatives
US20060205710A1 (en) Spiroazacyclic compounds as monoamine receptor modulators
EP1302458A1 (en) Ester derivatives
WO2003000677A1 (en) Spiropiperidine compounds as ligands for orl-1 receptor
WO1992020676A1 (en) Substituted 3-aminoquinuclidines
EP0528495A1 (en) Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
WO2003051840A1 (en) Pyrrolidine and piperidine derivates as nk1 antagonists
EP0577394A1 (en) Morpholine and thiomorpholine tachykinin receptor antagonists
EP0323864A2 (en) Lipophilic oxadiazoles
US5728695A (en) Spiroketal derivatives, compositions containing them and their use as therapeutic agents
EP0327155A2 (en) Pyrazines, pyrimidines and pyridazines, useful in the treatment of senile dementia
WO2003062224A1 (en) Aza-cyclic compounds as modulators of acetylcholine receptors
WO2009132000A1 (en) Quinoline or isoquinoline substituted p2x7 antagonists
WO2006101434A1 (en) NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS
WO2003015784A1 (en) 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
EP0499313B1 (en) Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
WO2007042250A1 (en) Prolinamide derivatives as sodium channel modulators
WO2008100621A2 (en) Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
US5852038A (en) Substituted 3-aminoquinuclidines
EP0359172A1 (en) Azabicycloalkanes
WO2015078374A1 (en) Substituted benzamides and methods of use thereof
WO2013004290A1 (en) Cyclic amine derivatives as ep4 receptor antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15703328

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 246599

Country of ref document: IL

ENP Entry into the national phase in:

Ref document number: 2936293

Country of ref document: CA

Ref document number: 2016545819

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016015609

Country of ref document: BR

ENP Entry into the national phase in:

Ref document number: 20167021356

Country of ref document: KR

Kind code of ref document: A

REEP

Ref document number: 2015703328

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201691413

Country of ref document: EA

ENP Entry into the national phase in:

Ref document number: 2015205001

Country of ref document: AU

Date of ref document: 20150106

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 112016015609

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160704